Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'Biosimilar-Biologics'
Biosimilar-Biologics published presentations and documents on DocSlides.
The generic and biosimilar
by alida-meadow
perspective. Warwick Smith. Director General BGMA...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
Comparison of US/EU Biosimilar
by aaron
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
U.S. Biosimilars: An Introduction
by calandra-battersby
Disclaimers. :. By 2016, 7 of the top 10 pharmace...
Comparison of US/EU Biosimilar
by myesha-ticknor
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Biosimilar Biological Products
by luanne-stotts
2016 . Clinical Investigator . Training Course. S...
PhAMA Position on Biosimilar Medicines
by celsa-spraggs
Ms. Leah Goodman. Contents. Key Messages. An Over...
Comparison of US/EU Biosimilar
by danika-pritchard
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
MODULE 8. Follow-on drugs: generic, biosimilar
by alida-meadow
& non-biological similar medicinal products ....
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by stefany-barnette
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
JMP for Biosimilars : Tools for Analytical Similarity
by erica
Sept 16, 2015. W. Heath Rushing, . Adsurgo. LLC. ...
INSIGHTS INTO THE MARKET
by summer
FOR INFLIXIMABTable of ContentsThe Evolving Landsc...
22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum
by carla
Adoption by CHMP for release for consultation24 Ma...
Phil Johnson MS RPh Safe School Meds, Principle Partner
by yoshiko-marsland
Moffitt Cancer Center, Director of Pharmacy (Reti...
Application of Biosimilars in RA IN Clinical Practice:
by conchita-marotz
Key Issues and Challenges. . Introduction. Diff...
Faculty Leonard H. Calabrese, DO
by trish-goza
Professor of Medicine. Cleveland Clinic Lerner Co...
Biological Products: concepts, naming,
by faustina-dinatale
interchangeability,extrapolation. and safety. Dr...
Analytical Similarity Assessment: Practical Challenges and Statistical Perspectives
by alida-meadow
Richard Montes, Ph.D.. Hospira. , a Pfizer compan...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMICS Group Biosimilars 2015 Birmingham, UK. 10-1...
Biosimilars in the Real World
by liane-varnes
Introduction/Overview . PLANETRA Extension Study:...
US Regulatory Pathway For Biosimilars
by cheryl-pisano
Practical Legal/Regulatory Considerations Arising...
Concurrent Session 1B
by yoshiko-marsland
View . from the Life Sciences . Industry. Moderat...
Biosimilars in RA: A Blessing or a Curse?
by conchita-marotz
Introduction/Overview . What Is a Biosimilar?. Di...
Biosimilars
by lindy-dunigan
Knowledge Connect Slide Resource. This slide dec...
Acceptable changes in quality attributes of glycosylated bi
by debby-jeon
Schiestl M, Stangler T, Torella C, et al. . Nat B...
Is Australia ready for
by liane-varnes
biosimilar. . ?. David Lim, Julie Hepworth, Lis...
What You Need to Know About
by marina-yarberry
Biosimilars. : Products, Recent Deals, IP Issues ...
Regulatory aspects and review
by mary
of EMA authorized . biosimilars. Session “Biosim...
Challenges in Assessing Therapeutic Equivalence of
by thomas
Nanosimilars. Beat . Flühmann. Global Lead NBCD ....
1 Immunogenicity The key safety issue for biosimilars
by gelbero
Prof. Ibrahim A. . Alsarra. Professor . of . Phar...
Prescription Drug Resource Center
by roberts
Generic Drug Substitution Laws May 3 , 2019 Compi...
NEUPOGEN filgrastim
by gelbero
GRANIX (tbo - filgrastim), NIVESTYM (filgrastim -...
Medicare Part B Step Therapy Programs
by elina
Page 1 of 10 UnitedHealthcare Medicare Advantag...
Improving Your Formulary and Denials Management
by trinity
Zinkeng Asonganyi, PharmD. Director of Pharmacy Se...
Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De
by anastasia
x0000x0000 x/Attxachexd /xBottxom x/BBoxx 3x014x33...
PSHP President’s Update
by myesha-ticknor
PSHP Annual Assembly. October 28, 2015. Matt Scol...
Biosimilars in emerging markets- regulatory and Commercial considerations
by jane-oiler
OMIC Group. Biosimilars 2104. Hyderabad. India. 2...
Latin American Physician Perspectives on Biosimilars
by celsa-spraggs
Presented at the . Latin American Biologics/Biosi...
National Pharmacy Practice
by debby-jeon
Gene Dorr . Area Vice President, PBM Consulting. ...
PSHP President’s Update
by olivia-moreira
PSHP Annual Assembly. October 28, 2015. Matt Scol...
Load More...
